6. パーキンソン病
[臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04269642 (ClinicalTrials.gov) | March 19, 2020 | 13/1/2020 | SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease | Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease | Early Parkinson's Disease | Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg | Peptron, Inc. | NULL | Recruiting | 40 Years | 75 Years | All | 99 | Phase 2 | Korea, Republic of |
2 | NCT04305002 (ClinicalTrials.gov) | January 21, 2020 | 20/2/2020 | Exenatide Treatment in Parkinson's Disease | Effect of Exenatide on Disease Progression in Early Parkinson's Disease | Parkinson Disease | Drug: Exenatide;Drug: Placebo | Center for Neurology, Stockholm | Karolinska Institutet | Recruiting | 25 Years | 80 Years | All | 60 | Phase 2 | Sweden |
3 | NCT04232969 (ClinicalTrials.gov) | January 20, 2020 | 10/1/2020 | Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease | A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease | Parkinson's Disease | Drug: Exenatide extended release 2mg (Bydureon) | University College, London | NULL | Recruiting | 25 Years | 80 Years | All | 200 | Phase 3 | United Kingdom |
4 | EUCTR2019-000732-26-SE (EUCTR) | 23/10/2019 | 07/05/2019 | Exenatide Treatment in Parkinson's Disease | Effect of Exenatide on disease progression in early Parkinson's disease. | Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension Product Name: BYDUREON INN or Proposed INN: EXENATIDE | Stockholm Health Care Services | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Sweden | ||
5 | EUCTR2018-003028-35-GB (EUCTR) | 04/09/2019 | 15/11/2019 | A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. | A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. - Phase 3 Trial of exenatide for Parkinson’s disease | Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | University College London Comprehensive Clinical Trial Unit | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 3 | United Kingdom | |||
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT03456687 (ClinicalTrials.gov) | June 5, 2018 | 1/3/2018 | Effects of Exenatide on Motor Function and the Brain | Effects of Exenatide on Motor Function and the Brain | Parkinson's Disease | Drug: Exenatide | University of Florida | National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 40 Years | 77 Years | All | 5 | Phase 1 | United States |
7 | NCT01971242 (ClinicalTrials.gov) | June 2014 | 23/10/2013 | Trial of Exenatide for Parkinson's Disease | A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease | Parkinson's Disease | Drug: Exenatide;Other: Placebo | University College, London | NULL | Completed | 25 Years | 75 Years | Both | 60 | Phase 2 | United Kingdom |
8 | EUCTR2013-003363-64-GB (EUCTR) | 03/04/2014 | 11/03/2014 | Trial of Exenatide for Parkinson's disease | A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease. - Exenatide-PD | Parkinson's Disease MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Bydureon Product Name: Exenatide INN or Proposed INN: exenatide | University College London | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | United Kingdom | ||
9 | NCT01174810 (ClinicalTrials.gov) | July 2010 | 2/8/2010 | Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study | An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease. | Parkinson's Disease | Drug: Exenatide | University College, London | NULL | Active, not recruiting | 45 Years | 70 Years | Both | 40 | Phase 2 | United Kingdom |
10 | EUCTR2009-018137-37-GB (EUCTR) | 14/04/2010 | 18/03/2010 | An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial | An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial | Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders | University College London | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United Kingdom |